Trade name: Etest family. Technical Name: Microorganism Identification / Antibiogram Device. ANVISA registration number: 10158120623. Class of risk: II. Affected model: Etest Polymyxin B. Serial number affected: 1002446640; 1002559300; 1002639240; 1002735070; 1002797130; 1003187220; 1003230410; 1003288010; 1003538020; 1003655420; 1003957060; 1004164300; 1004193060; 1004296350; 1004348480; 10044414690; 1004773920; 1004951670; 1005020680; 1005161530; 1005325780; 1005329410; 1005497750; 1005558710; 1005753830; 1005945380; 1002280140; 1002431510; 1002605340; 1002762220; 1002797270; 1003006080; 1003230380; 1003322180; 1003553910; 1003655460; 1003719640; 1004164310; 1004347610; 1004370570; 1004530070; 1004767110; 1004838770; 1004955950; 1005020690; 1005329420; 1005536040; 1005659460; 1005716410; 1005851010 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 bioMerieux Brasil Ind e Com de Prod Laboratoriais Ltda; Biomerieux S.A 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    2501
  • 날짜
    2018-02-27
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    Customers should be advised of nonconformity along with instructions to continue use of the impacted product with the limitation of not testing Pseudomonas and Acinetobacter strains with the Etest Polymyxin B product. Use is only recommended for Enterobacteriaceae. For tests released prior to this communication, we recommend that you identify any possible false-sensitive results that may have occurred for Pseudomonas aeruginosa and Acinetobacter in order to analyze the related risks and determine appropriate actions, if relevant. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution option; Entity, if you are a professional of an institution; entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link
  • 원인
    Following an etest polymyxin b study with 180 clinical strains (pseudomonas aeruginosa, acinetobacter and enterobacteriaceae), an underestimation of mics was observed with etest po (versus bmd) for pseudomonas aeruginosa and acinetobacter, which led to false susceptible results when interpreted with clsi breakpoints (note: there are no breakpoints in the eucast guidelines). as a consequence, etest polimixin b can no longer be recommended for use with pseudomonas aeruginosa or acinetobacter strains.
  • 조치
    Field Action Code FSCA 3763 triggered under the responsibility of the company bioMerieux Brasil Ind e Com de Prod Laboratoriais Ltda. Orientation of the clients regarding the actions defined.